regression using the HI and measured cTnI in the hemolyzed sample as variables to predict true cTnI concentration (the original pool cTnI concentration) was performed with Sigmastat 2.0 (Jandel Corporation). A single equation (r ϭ 0.91) was sufficient for the Access, whereas two equations (r ϭ 0.90 and 0.92) covering different HI ranges were needed for the ECi. At a HI of 9000 mg/L, models based on these equations predicted maximum differences in cTnI measurements of 0.33 g/L for the ECi assay and 0.02 g/L for the Access assay.
All samples received by the laboratory for routine ECi cTnI analysis for 7 days were also analyzed for HI and with the Access cTnI. The classification of individual results at different cTnI cutoffs, with and without hemolysis correction using the above equations, was calculated. Samples with cTnI concentrations higher than or equal to the cutoff before hemolysis correction but below it after correction were considered to be false positives.
We received 605 heparinized plasma samples for ECi cTnI analysis, of which 598 had sufficient volume for additional Access cTnI and HI measurements. Of these 598 samples, 6.2% were hemolyzed (4.2% with a HI of 1000 -2500 mg/L, 1.7% with a HI of 2500 -5000 mg/L, and 0.3% with a HI Ͼ5000 mg/L). Table 1 shows the percentage of false positives (number of false positives/total number of uncorrected cTnI results above cutoff) at different cutoffs (3 ). Although there were no false-positive cases at any cutoff concentration with the Access cTnI assay, the false-positive rate began to increase above zero at cutoffs Յ0.22 g/L with the ECi cTnI assay. This suggests that regardless of precision performance, cutoffs Ͻ0.22 g/L should not be used for the present formulation of the ECi cTnI assay.
This study demonstrates that he- 
Letters

Ortho-Clinical Diagnostics offers the following reply:
To the Editor: Interference by hemoglobin is clearly labeled in the VITROS ® Troponin I assay's "Instructions For Use" and Package Insert. The hemoglobin concentrations used and the differences measured are stated under "Limitations of the Procedure" (1 ).
Our upper reference limit (URL) study used a total of 768 fresh heparin-plasma samples from healthy individuals, which were collected at four different centers and tested with the VITROS Troponin I assay to establish a reference interval for healthy individuals and to validate the product claims in the Package Insert and Instructions For Use. No samples were excluded because of hemolysis, and only two samples (0.25%) were above the URL of 0.08 g/L (ng/mL).
The incidence of hemolyzed samples in Dr. Hawkins' study appears to be higher than our experience based on our customer service records. A hemoglobin concentration of 1000 mg/L (100 mg/dL) causes substantial discoloration of the sample, which can be easily observed by most laboratory technicians and therefore flagged for potential interferences.
We recommend that customers continue to use the cutoffs stated in our labeling for the VITROS Troponin I, i.e., 0.08 g/L as the URL and 0.4 g/L as the cutoff for acute myocardial infarction. Use of the cutoff of 0.22 g/L suggested by the author may lead to false negatives, which are clearly less desirable from a medical point of view than the false positives that may result from a small number of greatly hemolyzed samples that have not been excluded by good laboratory practice.
